Sanofi Pasteur and International Vaccine Institute Partner against Dengue

Sanofi-aventisSanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health agenda.

Currently, there is no specific treatment available for dengue fever, which is a threat to nearly half of the world's population and a public health priority in many countries of Latin America and Asia where epidemics occur. Of the estimated 220 million people infected annually, two million - mostly children - develop dengue hemorrhagic fever (DHF), a severe form of the disease (1). DHF is a leading cause of hospitalization, placing tremendous pressure on strained medical resources and having a heavy economic and societal impact.

"Each year, an estimated two million people with dengue hemorrhagic fever require hospitalization representing a significant burden on the fragile healthcare systems of developing and endemic nations," said Dr. Ragnar Norrby, Chairman of the Board of Trustees of IVI. "With a dengue vaccine on the short term horizon, this collaboration will focus on accelerating its adoption and introduction and on making it accessible to those at highest risk of dengue."

The International Vaccine Institute (IVI) announced the launch of the DVI on February 10, in collaboration with the Sabin Vaccine Institute, the Johns Hopkins University, and the World Health Organization, to support development of vaccines to control dengue fever.

"The fight against dengue requires a strong global commitment from all public health partners. The first dengue vaccine is now in the final stages of development. The IVI will be a key player in facilitating discussions among policy makers, with the objective of ensuring that once licensed the vaccine will be made available to those populations that need it most in a timely manner," stated Olivier Charmeil, Senior Vice President, sanofi-aventis, Vaccines.

About International Vaccine Institute
The International Vaccine Institute is an international organization devoted exclusively to developing and introducing new and improved vaccines for the world's poorest people, especially children in developing countries. The IVI conducts research in 30 countries in Asia, Africa, and Central and South America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, Japanese encephalitis, and dengue fever, and develops new and improved vaccines, delivery routes and adjuvants at its headquarters in Seoul, Korea.

About Dengue Vaccine Initiative
The Dengue Vaccine Initiative (DVI) was established in 2010 to build on the work of the Pediatric Dengue Vaccine Initiative and to further awareness of the need to support the development and use of dengue vaccines. The goal of the DVI is to accelerate the introduction of safe and broadly protective vaccines into the national immunization programs of endemic and developing countries. DVI works with scientists, vaccine experts and policy makers from concept to implementation, promoting the development of dengue vaccines while also advocating with governments worldwide to ensure the swift adoption and distribution of a vaccine to those most in need.

Sanofi Pasteur's global dengue vaccine clinical study program
Sanofi Pasteur's candidate dengue vaccine - which targets all four virus serotypes - is in Phase 3 clinical study. Phase 3 studies are the ultimate steps in the clinical development of a vaccine before it is submitted to regulatory authorities for evaluation for market authorization. Sanofi Pasteur candidate dengue vaccine has been evaluated in clinical studies (Phase 1, 2) in adults and children in the U.S., Asia and Latin America. Overall, a balanced immune response against all four serotypes was observed after three doses of the vaccine. The vaccine is well tolerated with a similar safety profile after each dose.(2)

Clinical studies in adults and children are ongoing in Mexico, Colombia, Honduras, Puerto Rico, Peru, the Philippines, Vietnam, Singapore, Australia, and Thailand.

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development.

1. PDVI Newsletter N° 7, April 2010 accessible at http://www.pdvi.org/PDFs/newsletters/PDVInewsletter7.pdf
2. Saville et al, Clinical development of a tetravalent dengue vaccine for endemic areas, ICID Miami, March 2010; Lang et al, Toward a tetravalent dengue vaccine in Brazil, Tropical Medicine meeting, Iguacu Falls, March 2010

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...